Publications by authors named "Thomas B Davis"

Claim this Profile
A
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Mingli Yang, Thomas B Davis, Lance Pflieger, Michael V Nebozhyn, Andrey Loboda

BMC Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer.
Thomas Benjamin Davis, Shilpa Gupta, Mingli Yang, Lance Pflieger, Malini Rajan

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes.
Ramya Thota, Mingli Yang, Lance Pflieger, Michael J Schell, Malini Rajan, Thomas B Davis

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC.
Thomas B Davis, Mingli Yang, Heiman Wang, Changgong Lee, Timothy J Yeatman

Oncotarget· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.
Thomas B Davis, Mingli Yang, Michael J Schell, Heiman Wang, Le Ma

Sci Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access to drug abuse treatment under Treatment on Demand policy in San Francisco.
James L Sorensen, Joseph Guydish, Pamela Zilavy, Thomas B Davis, Alice Gleghorn

Am J Drug Alcohol Abuse· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis